BB&T Investment Services Inc. acquired a new stake in Mednax, Inc (NYSE:MD) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 3,985 shares of the company’s stock, valued at approximately $243,000.
Several other institutional investors and hedge funds have also added to or reduced their stakes in MD. UBS Asset Management Americas Inc. lifted its position in shares of Mednax by 5.8% in the first quarter. UBS Asset Management Americas Inc. now owns 322,027 shares of the company’s stock valued at $22,342,000 after buying an additional 17,635 shares during the last quarter. Pacer Advisors Inc. lifted its position in shares of Mednax by 3.2% in the first quarter. Pacer Advisors Inc. now owns 1,795 shares of the company’s stock valued at $125,000 after buying an additional 55 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Mednax by 55.2% in the first quarter. JPMorgan Chase & Co. now owns 79,610 shares of the company’s stock valued at $5,524,000 after buying an additional 28,301 shares during the last quarter. KBC Group NV lifted its position in shares of Mednax by 79.6% in the first quarter. KBC Group NV now owns 13,382 shares of the company’s stock valued at $928,000 after buying an additional 5,931 shares during the last quarter. Finally, Prudential Financial Inc. lifted its position in shares of Mednax by 7.9% in the first quarter. Prudential Financial Inc. now owns 58,520 shares of the company’s stock valued at $4,060,000 after buying an additional 4,270 shares during the last quarter.
Mednax, Inc (NYSE MD) traded down 0.63% during trading on Friday, reaching $42.48. The company’s stock had a trading volume of 326,306 shares. The stock’s 50 day moving average is $43.11 and its 200 day moving average is $53.34. Mednax, Inc has a 12 month low of $40.78 and a 12 month high of $72.13. The company has a market cap of $3.92 billion, a price-to-earnings ratio of 13.53 and a beta of 0.37.
Mednax (NYSE:MD) last posted its earnings results on Friday, July 28th. The company reported $0.85 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.04. The firm had revenue of $843.00 million for the quarter, compared to the consensus estimate of $849.49 million. Mednax had a return on equity of 11.89% and a net margin of 8.78%. The business’s quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.03 earnings per share. On average, equities analysts expect that Mednax, Inc will post $3.30 EPS for the current fiscal year.
Several analysts recently weighed in on the company. Zacks Investment Research raised Mednax from a “sell” rating to a “hold” rating in a report on Wednesday. Jefferies Group LLC reissued a “hold” rating and set a $46.00 price target on shares of Mednax in a report on Tuesday, October 3rd. KeyCorp raised Mednax from a “sector weight” rating to an “overweight” rating and set a $51.00 price target for the company in a report on Sunday, September 17th. Robert W. Baird reissued a “hold” rating and set a $47.00 price target on shares of Mednax in a report on Sunday, September 3rd. Finally, BidaskClub cut Mednax from a “sell” rating to a “strong sell” rating in a report on Friday, August 4th. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have issued a buy rating to the stock. Mednax presently has a consensus rating of “Hold” and a consensus target price of $56.63.
In other Mednax news, insider John C. Pepia sold 3,000 shares of the stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $42.85, for a total transaction of $128,550.00. Following the sale, the insider now owns 35,569 shares in the company, valued at $1,524,131.65. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Corporate insiders own 2.40% of the company’s stock.
Mednax Company Profile
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.